Destiny Pharma
Ticker: DEST Exchange: AIM www.destinypharma.com

Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.

Interim 2022 results: oodles of progress

Destiny reported its H1 2022 financial results and provided an update on its pipeline progress. We have changed our forecasts and valuation to reflect both a lower spend than we had anticipated, and the predicted $10m (now £8.7m) licensing transaction before YE 2022.

Cash at the end of H1 2022 was £8.4m, (£7.1m at H1 2021), reflecting the recent fundraising and the lower H1 R&D spend than we had estimated, and provides a runway until at least mid-2023. Our YE 2022 estimate of cash is £12.1m, which includes our expectations of a licensing transaction.

The results release summarises the developments on pipeline, discussions with the regulators on its two Phase 3-ready assets, and what appears to be an accelerating pace of partnering activities: particularly on NTCD-M3. The attractiveness of these assets to licensing partners should have been increased by Destiny’s efforts.

Our valuation of Destiny has risen: from £209.6m (288p / share) to £251.2m (345p / share).

 
Download as a PDF file
26810392321 - destiny-pharma
Return to Destiny Pharma

Register to be first

Get research on the companies that interest you straight to your inbox

Register For Updates